GE HealthCare Technologies (NASDAQ:GEHC) Stock Rating Raised to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of GE HealthCare Technologies (NASDAQ:GEHC) from a hold rating to a buy rating in a research note released on Saturday,Wall Street Zen reports.

Several other research firms have also recently commented on GEHC. Wolfe Research assumed coverage on GE HealthCare Technologies in a research note on Tuesday, October 20th. They issued a “peer perform” rating for the company. Bank of America reaffirmed a “neutral” rating on shares of GE HealthCare Technologies in a research note on Thursday. BTIG Research raised their price target on GE HealthCare Technologies from $75.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday. Royal Bank Of Canada lifted their price objective on GE HealthCare Technologies from $80.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Wells Fargo & Company lifted their price objective on GE HealthCare Technologies from $75.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Twelve analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat.com, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and an average target price of $80.57.

GE HealthCare Technologies Trading Up 0.2%

GEHC stock opened at $76.57 on Friday. GE HealthCare Technologies has a fifty-two week low of $58.75 and a fifty-two week high of $89.77. The stock has a market capitalization of $34.62 billion, a price-to-earnings ratio of 16.15, a P/E/G ratio of 1.99 and a beta of 0.73. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.30 and a quick ratio of 0.97. The business has a fifty day moving average price of $68.45 and a 200 day moving average price of $70.06.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, October 28th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.20 by $0.14. GE HealthCare Technologies had a net margin of 9.96% and a return on equity of 20.45%. The business had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the prior year, the firm earned $1.07 earnings per share. GE HealthCare Technologies’s revenue was up 7.2% compared to the same quarter last year. Analysts expect that GE HealthCare Technologies will post 5.02 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a $0.04 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.0350. This represents a $0.16 annualized dividend and a yield of 0.2%. GE HealthCare Technologies’s payout ratio is currently 3.38%.

Institutional Trading of GE HealthCare Technologies

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp increased its holdings in GE HealthCare Technologies by 1.6% in the 2nd quarter. State Street Corp now owns 20,861,566 shares of the company’s stock worth $1,335,349,000 after purchasing an additional 323,090 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC raised its position in GE HealthCare Technologies by 13.2% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 13,455,814 shares of the company’s stock valued at $861,307,000 after purchasing an additional 1,571,226 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of GE HealthCare Technologies by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 5,399,439 shares of the company’s stock valued at $384,219,000 after purchasing an additional 105,995 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of GE HealthCare Technologies by 4.1% during the second quarter. Van ECK Associates Corp now owns 4,482,631 shares of the company’s stock valued at $286,933,000 after purchasing an additional 177,028 shares in the last quarter. Finally, Trian Fund Management L.P. grew its holdings in shares of GE HealthCare Technologies by 76,194.4% during the second quarter. Trian Fund Management L.P. now owns 3,085,344 shares of the company’s stock worth $197,493,000 after purchasing an additional 3,081,300 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Key GE HealthCare Technologies News

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Strong Q3 results beat expectations. GE HealthCare reported $5.51 billion in revenue, above the $5.35 billion consensus estimate, while EPS of $1.34 exceeded expectations of $1.20. Revenue increased 7.2% year over year, helping drive the post-earnings gap higher. GE HealthCare Technologies Shares Gap Up After Strong Earnings
• Positive Sentiment: Management raised its full-year outlook. The company now expects approximately 4% organic revenue growth, adjusted EPS of $4.95–$5.05, and at least $1.6 billion in free cash flow. Organic growth of 6.2% and margin expansion in the quarter further strengthened the bullish case. GE HealthCare: Broad-Based Growth Makes The Bull Case More Compelling
• Positive Sentiment: Analysts raised valuation targets. RBC increased its target from $80 to $90 and maintained an “outperform” rating. BNP Paribas lifted its target from $96 to $100, while Mizuho raised its target from $85 to $90. BTIG Research also forecast substantial potential appreciation. BNP Paribas Price Target Update
• Neutral Sentiment: JPMorgan raised its price target from $70 to $80 but kept a “neutral” rating, suggesting recognition of the earnings improvement while retaining a cautious stance on valuation. JPMorgan GE HealthCare Rating
• Neutral Sentiment: A value comparison with Haemonetics highlights GEHC’s investment appeal but does not introduce a material new catalyst for the stock. GEHC Versus HAE Value Comparison

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company’s portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.